Back to News
Market Impact: 0.42
Roivant Reports Positive Phase 2 Results For Mosliciguat In PH-ILD; Stock Up 17%
Source: Nasdaq
Healthcare & Biotech
Roivant reported that its Phase 2 PHocus trial of mosliciguat met both primary and secondary endpoints in adults with pulmonary hypertension associated with interstitial lung disease. The positive mid-stage clinical outcome de-risks the program and could support further development in an underserved indication.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.58
Ticker Sentiment
ROIV0.82
More News
- Vertex reports positive IgAN trial data, FDA decision due Nov. 30
- The real test for Moderna’s cancer vaccine isn’t about beating Keytruda. It’s keeping cancer from coming back in the long term.
- J&J prostate cancer drug shows promising tumor responses in early trial
- Oncologists Cheer Melanoma Data
- Investing.com’s stocks of the week
- Jefferies raises Zymeworks stock price target on Roche deal
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- AI Tools for Family Offices: A Stack by Decision Type
- Reading Conviction in the Tape: What Level 3 Order Book Data Really Tells Discretionary PMs